|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Katai H, Ishikawa T, Akazawa K, Isobe Y,
Miyashiro I, Oda I, Tsujitani S, Ono H, Tanabe S, Fukagawa T, et
al: Five-year survival analysis of surgically resected gastric
cancer cases in Japan: A retrospective analysis of more than
100,000 patients from the nationwide registry of the Japanese
Gastric Cancer Association (2001–2007). Gastric Cancer. 21:144–154.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sumiyama K: Erratum to: Past and current
trends in endoscopic diagnosis for early stage gastric cancer in
Japan. Gastric Cancer. 20:5622017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ren W, Yu J, Zhang ZM, Song YK, Li YH and
Wang L: Missed diagnosis of early gastric cancer or high-grade
intraepithelial neoplasia. World J Gastroenterol. 19:2092–2096.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Nie Y, Wu K, Yu J, Liang Q, Cai X, Shang
Y, Zhou J, Pan K, Sun L, Fang J, et al: A global burden of gastric
cancer: The major impact of China. Expert Rev Gastroenterol
Hepatol. 11:651–661. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Fock KM: Review article: The epidemiology
and prevention of gastric cancer. Aliment Pharmacol Ther.
40:250–260. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Li ZS and Li Q: The latest 2010 WHO
classification of tumors of digestive system. Zhonghua Bing Li Xue
Za Zhi. 40:351–354. 2011.(In Chinese). PubMed/NCBI
|
|
9
|
Plummer M, Franceschi S, Vignat J, Forman
D and de Martel C: Global burden of gastric cancer attributable to
Helicobacter pylori. Int J Cancer. 136:487–490. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Schistosomes, liver flukes and
Helicobacter pylori. IARC working group on the evaluation of
carcinogenic risks to humans. Lyon, 7–14 June 1994. IARC Monogr
Eval Carcinog Risks Hum. 61:1–241. 1994.PubMed/NCBI
|
|
11
|
van der Post RS, Vogelaar IP, Carneiro F,
Guilford P, Huntsman D, Hoogerbrugge N, Caldas C, Schreiber KE,
Hardwick RH, Ausems MG, et al: Hereditary diffuse gastric cancer:
Updated clinical guidelines with an emphasis on germline CDH1
mutation carriers. J Med Genet. 52:361–374. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Saigusa S, Tanaka K, Mohri Y, Ohi M,
Shimura T, Kitajima T, Kondo S, Okugawa Y, Toiyama Y, Inoue Y and
Kusunoki M: Clinical significance of RacGAP1 expression at the
invasive front of gastric cancer. Gastric Cancer. 18:84–92. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Catalano V, Labianca R, Beretta GD, Gatta
G, de Braud F and Van Cutsem E: Gastric cancer. Crit Rev Oncol
Hematol. 71:127–164. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lauren P: The two histological main types
of gastric carcinoma: Diffuse and so-called intestinal-type
carcinoma. An attempt at a histo-clinical classification. Acta
Pathol Microbiol Scand. 64:31–49. 1965. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Luu C, Thapa R, Woo K, Coppola D, Almhanna
K, Pimiento JM, Chen DT, Marquez DD and Hodul PJ: Does histology
really influence gastric cancer prognosis? J Gastrointest Oncol.
8:1026–1036. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
NIH-FDA conference: Biomarkers and
surrogate endpoints: Advancing clinical research and applications.
Abstracts. Dis Markers. 14:187–334. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Becking GC and Chen BH: International
programme on chemical safety (IPCS) environmental health criteria
on boron human health risk assessment. Biol Trace Elem Res.
66:439–452. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Abbas M, Habib M, Naveed M, Karthik K,
Dhama K, Shi M and Dingding C: The relevance of gastric cancer
biomarkers in prognosis and pre- and post-chemotherapy in clinical
practice. Biomed Pharmacother. 95:1082–1090. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Strimbu K and Tavel JA: What are
biomarkers? Curr Opin HIV AIDS. 5:463–466. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Meng FP, Ding J, Yu ZC, Han QL, Guo CC,
Liu N and Fan DM: Oral attenuated Salmonella typhimurium vaccine
against MG7-Ag mimotope of gastric cancer. World J Gastroenterol.
11:1833–1836. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ohtsu A, Yoshida S and Saijo N:
Disparities in gastric cancer chemotherapy between the East and
West. J Clin Oncol. 24:2188–2196. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tatsuta M, Itoh T, Okuda S, Yamamura H,
Baba M and Tamura H: Carcinoembryonic antigen in gastric juice as
an aid in diagnosis of early gastric cancer. Cancer. 46:2686–2692.
1980. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ishigami S, Natsugoe S, Hokita S, Che X,
Tokuda K, Nakajo A, Iwashige H, Tokushige M, Watanabe T, Takao S
and Aikou T: Clinical importance of preoperative carcinoembryonic
antigen and carbohydrate antigen 19-9 levels in gastric cancer. J
Clin Gastroenterol. 32:41–44. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yin LK, Sun XQ and Mou DZ: Value of
combined detection of serum CEA, CA72-4, CA19-9 and TSGF in the
diagnosis of gastric cancer. Asian Pac J Cancer Prev. 16:3867–3870.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ren J, Chen Z, Juan SJ, Yong XY, Pan BR
and Fan DM: Detection of circulating gastric carcinoma-associated
antigen MG7-Ag in human sera using an established single
determinant immuno-polymerase chain reaction technique. Cancer.
88:280–285. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Miki K, Ichinose M, Shimizu A, Huang SC,
Oka H, Furihata C, Matsushima T and Takahashi K: Serum pepsinogens
as a screening test of extensive chronic gastritis. Gastroenterol
Jpn. 22:133–141. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Miki K: Gastric cancer screening using the
serum pepsinogen test method. Gastric Cancer. 9:245–253. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Rugge M, Genta RM, Di Mario F, El-Omar EM,
El-Serag HB, Fassan M, Hunt RH, Kuipers EJ, Malfertheiner P, Sugano
K and Graham DY: Gastric cancer as preventable disease. Clin
Gastroenterol Hepatol. 15:1833–1843. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Graham DY: Helicobacter pylori
update: Gastric cancer, reliable therapy, and possible benefits.
Gastroenterology. 148:719–731.e3. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Konturek SJ, Starzynska T, Konturek PC,
Karczewska E, Marlicz K, Lawniczak M, Jaroszewicz-Heigelman H,
Bielanski W, Hartwich A, Ziemniak A and Hahn EG: Helicobacter
pylori and CagA status, serum gastrin, interleukin-8 and
gastric acid secretion in gastric cancer. Scand J Gastroenterol.
37:891–898. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Shiotani A, Iishi H, Uedo N, Kumamoto M,
Nakae Y, Ishiguro S, Tatsuta M and Graham DY: Histologic and serum
risk markers for noncardia early gastric cancer. Int J Cancer.
115:463–469. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Tu H, Sun L, Dong X, Gong Y, Xu Q, Jing J,
Bostick RM, Wu X and Yuan Y: A serological biopsy using five
stomach-specific circulating biomarkers for gastric cancer risk
assessment: A multi-phase study. Am J Gastroenterol. 112:704–715.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Shiroshita H, Watanabe H, Ajioka Y,
Watanabe G, Nishikura K and Kitano S: Re-evaluation of mucin
phenotypes of gastric minute well-differentiated-type
adenocarcinomas using a series of HGM, MUC5AC, MUC6, M-GGMC, MUC2
and CD10 stains. Pathol Int. 54:311–321. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Camargo MC, Murphy G, Koriyama C, Pfeiffer
RM, Kim WH, Herrera-Goepfert R, Corvalan AH, Carrascal E, Abdirad
A, Anwar M, et al: Determinants of Epstein-Barr virus-positive
gastric cancer: An international pooled analysis. Br J Cancer.
105:38–43. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhou Y, Zhang GJ, Wang J, Zheng KY and Fu
W: Current status of lymph node micrometastasis in gastric cancer.
Oncotarget. 8:51963–51969. 2017.PubMed/NCBI
|
|
36
|
Hata M, Machi J, Mamou J, Yanagihara ET,
Saegusa-Beecroft E, Kobayashi GK, Wong CC, Fung C, Feleppa EJ and
Sakamoto K: Entire-volume serial histological examination for
detection of micrometastases in lymph nodes of colorectal cancers.
Pathol Oncol Res. 17:835–841. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Giorgadze TA, Baloch ZW, Pasha T, Zhang PJ
and Livolsi VA: Lymphatic and blood vessel density in the
follicular patterned lesions of thyroid. Mod Pathol. 18:1424–1431.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Moore BW: A soluble protein characteristic
of the nervous system. Biochem Biophys Res Commun. 19:739–744.
1965. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Abdel-Aziz A, Ahmed RA and Ibrahiem AT:
Expression of pRb, Ki67 and HER 2/neu in gastric carcinomas:
Relation to different histopathological grades and stages. Ann
Diagn Pathol. 30:1–7. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Yerushalmi R, Woods R, Ravdin PM, Hayes MM
and Gelmon KA: Ki67 in breast cancer: Prognostic and predictive
potential. Lancet Oncol. 11:174–183. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Genc CG, Falconi M, Partelli S, Muffatti
F, van Eeden S, Doglioni C, Klumpen HJ, van Eijck C and Nieveen
VDE: Recurrence of pancreatic neuroendocrine tumors and survival
predicted by Ki67. Ann Surg Oncol. 25:2467–2474. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Akiyama T, Sudo C, Ogawara H, Toyoshima K
and Yamamoto T: The product of the human c-erbB-2 gene: A
185-kilodalton glycoprotein with tyrosine kinase activity. Science.
232:1644–1646. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Liu L, Wu N and Li J: Novel targeted
agents for gastric cancer. J Hematol Oncol. 5:312012. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Bang YJ, Van Cutsem E, Feyereislova A,
Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T,
et al: Trastuzumab in combination with chemotherapy versus
chemotherapy alone for treatment of HER2-positive advanced gastric
or gastro-oesophageal junction cancer (ToGA): A phase 3,
open-label, randomised controlled trial. Lancet. 376:687–697. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Tanner M, Hollmén M, Junttila TT, Kapanen
AI, Tommola S, Soini Y, Helin H, Salo J, Joensuu H, Sihvo E, et al:
Amplification of HER-2 in gastric carcinoma: Association with
topoisomerase IIalpha gene amplification, intestinal type, poor
prognosis and sensitivity to trastuzumab. Ann Oncol. 16:273–278.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Gravalos C and Jimeno A: HER2 in gastric
cancer: A new prognostic factor and a novel therapeutic target. Ann
Oncol. 19:1523–1529. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Wood DE, Kazerooni E, Baum SL, Dransfield
MT, Eapen GA, Ettinger DS, Hou L, Jackman DM, Klippenstein D, Kumar
R, et al: Lung cancer screening, version 1.2015: Featured updates
to the NCCN guidelines. J Natl Compr Canc Netw. 13:23–34. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Ruschoff J, Hanna W, Bilous M, Hofmann M,
Osamura RY, Penault-Llorca F, van de Vijver M and Viale G: HER2
testing in gastric cancer: A practical approach. Mod Pathol.
25:637–650. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Ohtsu A, Shah MA, Van Cutsem E, Rha SY,
Sawaki A, Park SR, Lim HY, Yamada Y, Wu J, Langer B, et al:
Bevacizumab in combination with chemotherapy as first-line therapy
in advanced gastric cancer: A randomized, double-blind,
placebo-controlled phase III study. J Clin Oncol. 29:3968–3976.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Hu X, Cao J, Hu W, Wu C, Pan Y, Cai L,
Tong Z, Wang S, Li J, Wang Z, et al: Multicenter phase II study of
apatinib in non-triple-negative metastatic breast cancer. Bmc
Cancer. 14:8202014. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Derde LPG, Cooper BS, Goossens H,
Malhotra-Kumar S, Willems RJL, Gniadkowski M, Hryniewicz W, Empel
J, Dautzenberg M, Annane D, et al: Interventions to reduce
colonisation and transmission of antimicrobial-resistant bacteria
in intensive care units: An interrupted time series study and
cluster randomised trial. Lancet Infect Dis. 14:31–39. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Lee J and Ou SH: Towards the goal of
personalized medicine in gastric cancer-time to move beyond HER2
inhibition. Part II: Targeting gene mutations and gene
amplifications and the angiogenesis pathway. Discov Med. 16:7–14.
2013.PubMed/NCBI
|
|
53
|
Javle M, Li Y, Tan D, Dong X, Chang P, Kar
S and Li D: Biomarkers of TGF-β signaling pathway and prognosis of
pancreatic cancer. PLoS One. 9:e859422014. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Elice F, Rodeghiero F, Falanga A and
Rickles FR: Thrombosis associated with angiogenesis inhibitors.
Best Pract Res Clin Haematol. 22:115–128. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Westover D, Zugazagoitia J, Cho BC, Lovly
CM and Paz-Ares L: Mechanisms of acquired resistance to first- and
second-generation EGFR tyrosine kinase inhibitors. Ann Oncol. 29
(Suppl 1):i10–i19. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Wainberg ZA, Anghel A, Desai AJ, Ayala R,
Luo T, Safran B, Fejzo MS, Hecht JR, Slamon DJ and Finn RS:
Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively
inhibits HER2-amplified human gastric cancer cells and is
synergistic with trastuzumab in vitro and in vivo. Clin Cancer Res.
16:1509–1519. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Lordick F, Kang YK, Chung HC, Salman P, Oh
SC, Bodoky G, Kurteva G, Volovat C, Moiseyenko VM, Gorbunova V, et
al: Capecitabine and cisplatin with or without cetuximab for
patients with previously untreated advanced gastric cancer
(EXPAND): A randomised, open-label phase 3 trial. Lancet Oncol.
14:490–499. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Waddell T, Chau I, Cunningham D, Gonzalez
D, Okines AF, Okines C, Wotherspoon A, Saffery C, Middleton G,
Wadsley J, et al: Epirubicin, oxaliplatin, and capecitabine with or
without panitumumab for patients with previously untreated advanced
oesophagogastric cancer (REAL3): A randomised, open-label phase 3
trial. Lancet Oncol. 14:481–489. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Liu X, Guo W, Zhang W, Yin J, Zhang J, Zhu
X, Liu T, Chen Z, Wang B, Chang J, et al: A multi-center phase II
study and biomarker analysis of combined cetuximab and modified
FOLFIRI as second-line treatment in patients with metastatic
gastric cancer. BMC Cancer. 17:1882017. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Tebbutt NC, Price TJ, Ferraro DA, Wong N,
Veillard AS, Hall M, Sjoquist KM, Pavlakis N, Strickland A, Varma
SC, et al: Panitumumab added to docetaxel, cisplatin and
fluoropyrimidine in oesophagogastric cancer: ATTAX3 phase II trial.
Br J Cancer. 114:505–509. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Kim MA, Lee HS, Lee HE, Jeon YK, Yang HK
and Kim WH: EGFR in gastric carcinomas: Prognostic significance of
protein overexpression and high gene copy number. Histopathology.
52:738–746. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Catenacci D, Tebbutt NC, Davidenko I,
Murad AM, Al-Batran SE, Ilson DH, Tjulandin S, Gotovkin E,
Karaszewska B and Bondarenko I: Rilotumumab plus epirubicin,
cisplatin, and capecitabine as first-line therapy in advanced
MET-positive gastric or gastro-oesophageal junction cancer
(RILOMET-1): A randomised, double-blind, placebo-controlled, phase
3 trial. Lancet Oncol. 18:1467–1482. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Ha SY, Lee J, Kang SY, Do IG, Ahn S, Park
JO, Kang WK, Choi MG, Sohn TS and Bae JM: MET overexpression
assessed by new interpretation method predicts gene amplification
and poor survival in advanced gastric carcinomas. Mod Pathol.
26:1632–1641. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Lee SJ, Lee J, Park SH, Park JO, Lim HY,
Kang WK, Park YS and Kim ST: c-MET overexpression in colorectal
cancer: A poor prognostic factor for survival. Clin Colorectal
Cancer. 17:165–169. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Pasquini G and Giaccone G: C-MET
inhibitors for advanced non-small cell lung cancer. Expert Opin
Investig Drugs. 27:363–375. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Kuboki Y, Matsusaka S, Minowa S, Shibata
H, Suenaga M, Shinozaki E, Mizunuma N, Ueno M, Yamaguchi T and
Hatake K: Circulating tumor cell (CTC) count and epithelial growth
factor receptor expression on CTCs as biomarkers for cetuximab
efficacy in advanced colorectal cancer. Anticancer Res.
33:3905–3910. 2013.PubMed/NCBI
|
|
67
|
Catenacci DV, Henderson L, Xiao SY, Patel
P, Yauch RL, Hegde P, Zha J, Pandita A, Peterson A and Salgia R:
Durable complete response of metastatic gastric cancer with
anti-Met therapy followed by resistance at recurrence. Cancer
Discov. 1:573–579. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Al-Batran SE, Ducreux M and Ohtsu A: mTOR
as a therapeutic target in patients with gastric cancer. Int J
Cancer. 130:491–496. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Ohtsu A, Ajani JA, Bai YX, Bang YJ, Chung
HC, Pan HM, Sahmoud T, Shen L, Yeh KH, Chin K, et al: Everolimus
for previously treated advanced gastric cancer: Results of the
randomized, double-blind, phase III GRANITE-1 study. J Clin Oncol.
31:3935–3943. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Wainberg ZA, Soares HP, Patel R, DiCarlo
B, Park DJ, Liem A, Wang HJ, Yonemoto L, Martinez D, Laux I, et al:
Phase II trial of everolimus in patients with refractory metastatic
adenocarcinoma of the esophagus, gastroesophageal junction and
stomach: Possible role for predictive biomarkers. Cancer Chemother
Pharmacol. 76:61–67. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Al-Batran SE, Hofheinz RD, Pauligk C, Kopp
HG, Haag GM, Luley KB, Meiler J, Homann N, Lorenzen S, Schmalenberg
H, et al: Histopathological regression after neoadjuvant docetaxel,
oxaliplatin, fluorouracil, and leucovorin versus epirubicin,
cisplatin, and fluorouracil or capecitabine in patients with
resectable gastric or gastro-oesophageal junction adenocarcinoma
(FLOT4-AIO): Results from the phase 2 part of a multicentre,
open-label, randomised phase 2/3 trial. Lancet Oncol. 17:1697–1708.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Singh P, Toom S and Huang Y: Anti-claudin
18.2 antibody as new targeted therapy for advanced gastric cancer.
J Hematol Oncol. 10:1052017. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Chen X, Wang M, Yang X, Wang Y, Yu L, Sun
J and Ding J: Injectable hydrogels for the sustained delivery of a
HER2-targeted antibody for preventing local relapse of
HER2+ breast cancer after breast-conserving surgery.
Theranostics. 9:6080–6098. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Tan IB, Ivanova T, Lim KH, Ong CW, Deng N,
Lee J, Tan SH, Wu J, Lee MH, Ooi CH, et al: Intrinsic subtypes of
gastric cancer, based on gene expression pattern, predict survival
and respond differently to chemotherapy. Gastroenterology.
141:476–485, 485.e1-e11. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Lei Z, Tan IB, Das K, Deng N, Zouridis H,
Pattison S, Chua C, Feng Z, Guan YK, Ooi CH, et al: Identification
of molecular subtypes of gastric cancer with different responses to
PI3-kinase inhibitors and 5-fluorouracil. Gastroenterology.
145:554–565. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Cancer Genome Atlas Research Network, .
Comprehensive molecular characterization of gastric adenocarcinoma.
Nature. 513:202–209. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Cristescu R, Lee J, Nebozhyn M, Kim KM,
Ting JC, Wong SS, Liu J, Yue YG, Wang J, Yu K, et al: Molecular
analysis of gastric cancer identifies subtypes associated with
distinct clinical outcomes. Nat Med. 21:449–456. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Keir ME, Butte MJ, Freeman GJ and Sharpe
AH: PD-1 and its ligands in tolerance and immunity. Annu Rev
Immunol. 26:677–704. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Pardoll DM: The blockade of immune
checkpoints in cancer immunotherapy. Nat Rev Cancer. 12:252–264.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Topalian SL, Drake CG and Pardoll DM:
Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor
immunity. Curr Opin Immunol. 24:207–212. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Kim JW, Nam KH, Ahn SH, Park DJ, Kim HH,
Kim SH, Chang H, Lee JO, Kim YJ, Lee HS, et al: Prognostic
implications of immunosuppressive protein expression in tumors as
well as immune cell infiltration within the tumor microenvironment
in gastric cancer. Gastric Cancer. 19:42–52. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Qing Y, Li Q, Ren T, Xia W, Peng Y, Liu
GL, Luo H, Yang YX, Dai XY, Zhou SF and Wang D: Upregulation of
PD-L1 and APE1 is associated with tumorigenesis and poor prognosis
of gastric cancer. Drug Des Devel Ther. 9:901–909. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Taube JM, Anders RA, Young GD, Xu H,
Sharma R, McMiller TL, Chen S, Klein AP, Pardoll DM, Topalian SL
and Chen L: Colocalization of inflammatory response with B7-h1
expression in human melanocytic lesions supports an adaptive
resistance mechanism of immune escape. Sci Transl Med.
4:127ra372012. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Sun J, Xu K, Wu C, Wang Y, Hu Y, Zhu Y,
Chen Y, Shi Q, Yu G and Zhang X: PD-L1 expression analysis in
gastric carcinoma tissue and blocking of tumor-associated PD-L1
signaling by two functional monoclonal antibodies. Tissue Antigens.
69:19–27. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Kang YK, Boku N, Satoh T, Ryu MH, Chao Y,
Kato K, Chung HC, Chen JS, Muro K, Kang WK, et al: Nivolumab in
patients with advanced gastric or gastro-oesophageal junction
cancer refractory to, or intolerant of, at least two previous
chemotherapy regimens (ONO-4538-12, ATTRACTION-2): A randomised,
double-blind, placebo-controlled, phase 3 trial. Lancet.
390:2461–2471. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Patnaik A, Kang SP, Rasco D, Papadopoulos
KP, Elassaiss-Schaap J, Beeram M, Drengler R, Chen C, Smith L,
Espino G, et al: Phase I study of pembrolizumab (MK-3475; Anti-PD-1
Monoclonal Antibody) in patients with advanced solid tumors. Clin
Cancer Res. 21:4286–4293. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Giuliani J and Bonetti A:
Immune-checkpoint inhibitors in head and neck squamous cell
carcinoma: Cost-efficacy in second-line treatment based on
programmed death-ligand 1 (PD-L1) level. Oral Oncol. 97:143–145.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Kerr KM and Hirsch FR: Programmed death
ligand-1 immunohistochemistry: Friend or foe? Arch Pathol Lab Med.
140:326–331. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Boyiadzis M, Bishop MR, Abonour R,
Anderson KC, Ansell SM, Avigan D, Barbarotta L, Barrett AJ, Van
Besien K, Bergsagel PL, et al: The society for immunotherapy of
cancer consensus statement on immunotherapy for the treatment of
hematologic malignancies: Multiple myeloma, lymphoma, and acute
leukemia. J Immunother Cancer. 4:902016. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Gettinger S, Horn L, Jackman D, Spigel D,
Antonia S, Hellmann M, Powderly J, Heist R, Sequist LV, Smith DC,
et al: Five-year follow-up of nivolumab in previously treated
advanced non-small-cell lung cancer: Results from the CA209-003
study. J Clin Oncol. 36:1675–1684. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Hou J, Yu Z, Xiang R, Li C and Wang L,
Chen S, Li Q, Chen M and Wang L: Correlation between infiltration
of FOXP3+ regulatory T cells and expression of B7-H1 in
the tumor tissues of gastric cancer. Exp Mol Pathol. 96:284–291.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Geng Y, Wang H, Lu C, Li Q, Xu B, Jiang J
and Wu C: Expression of costimulatory molecules B7-H1, B7-H4 and
Foxp3+ Tregs in gastric cancer and its clinical
significance. Int J Clin Oncol. 20:273–281. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Muro K, Chung HC, Shankaran V, Geva R,
Catenacci D, Gupta S, Eder JP, Golan T, Le DT, Burtness B, et al:
Pembrolizumab for patients with PD-L1-positive advanced gastric
cancer (KEYNOTE-012): A multicentre, open-label, phase 1b trial.
Lancet Oncol. 17:717–726. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Fuchs CS, Doi T, Jang RW, Muro K, Satoh T,
Machado M, Sun W, Jalal SI, Shah MA, Metges JP, et al: Safety and
efficacy of pembrolizumab monotherapy in patients with previously
treated advanced gastric and gastroesophageal junction cancer:
Phase 2 Clinical KEYNOTE-059 Trial. JAMA Oncol. 4:e1800132018.
View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Hamid O, Puzanov I, Dummer R, Schachter J,
Daud A, Schadendorf D, Blank C, Cranmer LD, Robert C, Pavlick AC,
et al: Final analysis of a randomised trial comparing pembrolizumab
versus investigator-choice chemotherapy for ipilimumab-refractory
advanced melanoma. Eur J Cancer. 86:37–45. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Fashoyin-Aje L, Donoghue M, Chen H, He K,
Veeraraghavan J, Goldberg KB, Keegan P, McKee AE and Pazdur R: FDA
approval summary: Pembrolizumab for recurrent locally advanced or
metastatic gastric or gastroesophageal junction adenocarcinoma
expressing PD-L1. Oncologist. 24:103–109. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Joshi SS, Maron SB and Catenacci DV:
Pembrolizumab for treatment of advanced gastric and
gastroesophageal junction adenocarcinoma. Future Oncol. 14:417–430.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Sohn BH, Hwang JE, Jang HJ, Lee HS, Oh SC,
Shim JJ, Lee KW, Kim EH, Yim SY, Lee SH, et al: Clinical
significance of four molecular subtypes of gastric cancer
identified by the cancer genome atlas project. Clin Cancer Res. Jul
26–2017.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Derks S, Liao X, Chiaravalli AM, Xu X,
Camargo MC, Solcia E, Sessa F, Fleitas T, Freeman GJ, Rodig SJ, et
al: Abundant PD-L1 expression in epstein-barr virus-infected
gastric cancers. Oncotarget. 7:32925–32932. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Ma C, Patel K, Singhi AD, Ren B, Zhu B,
Shaikh F and Sun W: Programmed death-ligand 1 expression is common
in gastric cancer associated with epstein-barr virus or
microsatellite instability. Am J Surg Pathol. 40:1496–1506. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Qiu H and Zhou Z: Updates and
interpretation on NCCN clinical practice guidelines for gastric
cancer 2017 version 5. Zhonghua Wei Chang Wai Ke Za Zhi.
21:160–164. 2018.(In Chinese). PubMed/NCBI
|
|
102
|
Yarchoan M, Hopkins A and Jaffee EM: Tumor
mutational burden and response rate to PD-1 inhibition. N Engl J
Med. 377:2500–2501. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Hellmann MD, Callahan MK, Awad MM, Calvo
E, Ascierto PA, Atmaca A, Rizvi NA, Hirsch FR, Selvaggi G,
Szustakowski JD, et al: Tumor mutational burden and efficacy of
nivolumab monotherapy and in combination with ipilimumab in
small-cell lung cancer. Cancer Cell. 33:853–861.e4. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Hellmann MD, Ciuleanu TE, Pluzanski A, Lee
JS, Otterson GA, Audigier-Valette C, Minenza E, Linardou H, Burgers
S, Salman P, et al: Nivolumab plus ipilimumab in lung cancer with a
high tumor mutational burden. N Engl J Med. 378:2093–2104. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Das PM and Singal R: DNA methylation and
cancer. J Clin Oncol. 22:4632–4642. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Mitsuno M, Kitajima Y, Ide T, Ohtaka K,
Tanaka M, Satoh S and Miyazaki K: Aberrant methylation of p16
predicts candidates for 5-fluorouracil-based adjuvant therapy in
gastric cancer patients. J Gastroenterol. 42:866–873. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Leung WK, To KF, Chu ES, Chan MW, Bai AH,
Ng EK, Chan FK and Sung JJ: Potential diagnostic and prognostic
values of detecting promoter hypermethylation in the serum of
patients with gastric cancer. Br J Cancer. 92:2190–2194. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Ikoma H, Ichikawa D, Daito I, Nobuyuki T,
Koike H, Okamoto K, Ochiai T, Ueda Y, Yamagishi H and Otsuji E:
Clinical application of methylation specific-polymerase chain
reaction in serum of patients with gastric cancer.
Hepatogastroenterology. 54:946–950. 2007.PubMed/NCBI
|
|
109
|
Sakakura C, Hamada T, Miyagawa K, Nishio
M, Miyashita A, Nagata H, Ida H, Yazumi S, Otsuji E and Chiba T:
Quantitative analysis of tumor-derived methylated RUNX3 sequences
in the serum of gastric cancer patients. Anticancer Res.
29:2619–2625. 2009.PubMed/NCBI
|
|
110
|
Homma N, Tamura G, Honda T, Matsumoto Y,
Nishizuka S, Kawata S and Motoyama T: Spreading of methylation
within RUNX3 CpG island in gastric cancer. Cancer Sci. 97:51–56.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Chen CC, Lee KD, Pai MY, Chu PY, Hsu CC,
Chiu CC, Chen LT, Chang JY, Hsiao SH and Leu YW: Changes in DNA
methylation are associated with the development of drug resistance
in cervical cancer cells. Cancer Cell Int. 15:982015. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Choi SJ, Jung SW, Huh S, Chung YS, Cho H
and Kang H: Alteration of DNA methylation in gastric cancer with
chemotherapy. J Microbiol Biotechnol. 27:1367–1378. 2017.PubMed/NCBI
|
|
113
|
Djebali S, Davis CA, Merkel A, Dobin A,
Lassmann T, Mortazavi A, Tanzer A, Lagarde J, Lin W, Schlesinger F,
et al: Landscape of transcription in human cells. Nature.
489:101–108. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Guttman M and Rinn JL: Modular regulatory
principles of large non-coding RNAs. Nature. 482:339–346. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Kwok ZH and Tay Y: Long noncoding RNAs:
Lincs between human health and disease. Biochem Soc Trans.
45:805–812. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Bartel DP and Chen CZ: Micromanagers of
gene expression: The potentially widespread influence of metazoan
microRNAs. Nat Rev Genet. 5:396–400. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Liu N, Chen NY, Cui RX, Li WF, Li Y, Wei
RR, Zhang MY, Sun Y, Huang BJ, Chen M, et al: Prognostic value of a
microRNA signature in nasopharyngeal carcinoma: A microRNA
expression analysis. Lancet Oncol. 13:633–641. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Yasui W, Sentani K, Sakamoto N, Anami K,
Naito Y and Oue N: Molecular pathology of gastric cancer: Research
and practice. Pathol Res Pract. 207:608–612. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Wu WK, Lee CW, Cho CH, Fan D, Wu K, Yu J
and Sung JJ: MicroRNA dysregulation in gastric cancer: A new player
enters the game. Oncogene. 29:5761–5771. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Ueda T, Volinia S, Okumura H, Shimizu M,
Taccioli C, Rossi S, Alder H, Liu CG, Oue N, Yasui W, et al:
Relation between microRNA expression and progression and prognosis
of gastric cancer: A microRNA expression analysis. Lancet Oncol.
11:136–146. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Yang TS, Yang XH, Wang XD, Wang YL, Zhou B
and Song ZS: MiR-214 regulate gastric cancer cell proliferation,
migration and invasion by targeting PTEN. Cancer Cell Int.
13:682013. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Zheng B, Liang L, Wang C, Huang S, Cao X,
Zha R, Liu L, Jia D, Tian Q, Wu J, et al: MicroRNA-148a suppresses
tumor cell invasion and metastasis by downregulating ROCK1 in
gastric cancer. Clin Cancer Res. 17:7574–7583. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Xu Y, Zhao F, Wang Z, Song Y, Luo Y, Zhang
X, Jiang L, Sun Z, Miao Z and Xu H: MicroRNA-335 acts as a
metastasis suppressor in gastric cancer by targeting Bcl-w and
specificity protein 1. Oncogene. 31:1398–1407. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Zhang X, Cui L, Ye G, Zheng T, Song H, Xia
T, Yu X, Xiao B, Le Y and Guo J: Gastric juice microRNA-421 is a
new biomarker for screening gastric cancer. Tumour Biol.
33:2349–2355. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Bhan A and Mandal SS: Long noncoding RNAs:
Emerging stars in gene regulation, epigenetics and human disease.
ChemMedChem. 9:1932–1956. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Zhou X, Yin C, Dang Y, Ye F and Zhang G:
Identification of the long non-coding RNA H19 in plasma as a novel
biomarker for diagnosis of gastric cancer. Sci Rep. 5:115162015.
View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Yang F, Bi J, Xue X, Zheng L, Zhi K, Hua J
and Fang G: Up-regulated long non-coding RNA H19 contributes to
proliferation of gastric cancer cells. FEBS J. 279:3159–3165. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Pang Q, Ge J, Shao Y, Sun W, Song H, Xia
T, Xiao B and Guo J: Increased expression of long intergenic
non-coding RNA LINC00152 in gastric cancer and its clinical
significance. Tumour Biol. 35:5441–5447. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Zheng Q, Wu F, Dai WY, Zheng DC, Zheng C,
Ye H, Zhou B, Chen JJ and Chen P: Aberrant expression of UCA1 in
gastric cancer and its clinical significance. Clin Transl Oncol.
17:640–646. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Dong L, Qi P, Xu MD, Ni SJ, Huang D, Xu
QH, Weng WW, Tan C, Sheng WQ, Zhou XY, et al: Circulating CUDR,
LSINCT-5 and PTENP1 long noncoding RNAs in sera distinguish
patients with gastric cancer from healthy controls. Int J Cancer.
137:1128–1135. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Memczak S, Jens M, Elefsinioti A, Torti F,
Krueger J, Rybak A, Maier L, Mackowiak SD, Gregersen LH, Munschauer
M, et al: Circular RNAs are a large class of animal RNAs with
regulatory potency. Nature. 495:333–338. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Hentze MW and Preiss T: Circular RNAs:
Splicing's enigma variations. EMBO J. 32:923–925. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Liu H, Liu Y, Bian Z, Zhang J, Zhang R,
Chen X, Huang Y, Wang Y and Zhu J: Circular RNA YAP1 inhibits the
proliferation and invasion of gastric cancer cells by regulating
the miR-367-5p/p27 Kip1 axis. Mol Cancer. 17:1512018.
View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Lyu D and Huang S: The emerging role and
clinical implication of human exonic circular RNA. Rna Biol.
14:1000–1006. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Qu S, Zhong Y, Shang R, Zhang X, Song W,
Kjems J and Li H: The emerging landscape of circular RNA in life
processes. Rna Biol. 14:992–999. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Chen J, Li Y, Zheng Q, Bao C, He J, Chen
B, Lyu D, Zheng B, Xu Y, Long Z, et al: Circular RNA profile
identifies circPVT1 as a proliferative factor and prognostic marker
in gastric cancer. Cancer Lett. 388:208–219. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Chen S, Li T, Zhao Q, Xiao B and Guo J:
Using circular RNA hsa_circ_0000190 as a new biomarker in the
diagnosis of gastric cancer. Clin Chim Acta. 466:167–171. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Li P, Chen H, Chen S, Mo X, Li T, Xiao B,
Yu R and Guo J: Circular RNA 0000096 affects cell growth and
migration in gastric cancer. Br J Cancer. 116:626–633. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Li P, Chen S, Chen H, Mo X, Li T, Shao Y,
Xiao B and Guo J: Using circular RNA as a novel type of biomarker
in the screening of gastric cancer. Clin Chim Acta. 444:132–136.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
140
|
Kawakami M, Mustachio LM,
Rodriguez-Canales J, Mino B, Roszik J, Tong P, Wang J, Lee JJ,
Myung JH, Heymach JV, et al: Next-generation CDK2/9 inhibitors and
anaphase catastrophe in lung cancer. J Natl Cancer Inst. 109:2017.
View Article : Google Scholar : PubMed/NCBI
|
|
141
|
Zohny SF, Baothman OA, El-Shinawi M,
Al-Malki AL, Zamzami MA and Choudhry H: The KIP/CIP family members
p21^{Waf1/Cip1} and p57^{Kip2} as diagnostic markers for breast
cancer. Cancer Biomark. 18:413–423. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
142
|
Tenderenda M: A study on the prognostic
value of cyclins D1 and E expression levels in resectable gastric
cancer and on some correlations between cyclins expression,
histoclinical parameters and selected protein products of
cell-cycle regulatory genes. J Exp Clin Cancer Res. 24:405–414.
2005.PubMed/NCBI
|
|
143
|
Nitti D, Belluco C, Mammano E, Marchet A,
Ambrosi A, Mencarelli R, Segato P and Lise M: Low level of
p27(Kip1) protein expression in gastric adenocarcinoma is
associated with disease progression and poor outcome. J Surg Oncol.
81:167–176. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
144
|
Xiangming C, Natsugoe S, Takao S, Hokita
S, Tanabe G, Baba M, Kuroshima K and Aikou T: The cooperative role
of p27 with cyclin E in the prognosis of advanced gastric
carcinoma. Cancer. 89:1214–1219. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
145
|
Sgambato A, Migaldi M, Leocata P, Ventura
L, Criscuolo M, Di Giacomo C, Capelli G, Cittadini A and De Gaetani
C: Loss of p27Kip1 expression is a strong independent prognostic
factor of reduced survival in N0 gastric carcinomas. Cancer.
89:2247–2257. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
146
|
Ichiyoshi Y, Oiwa H, Tomisaki S, Sakaguchi
Y, Ohno S, Maehara Y and Sugimachi K: Overexpression of p53 is
associated with growth pattern and prognosis in advanced gastric
cancer. Hepatogastroenterology. 44:546–553. 1997.PubMed/NCBI
|
|
147
|
Lowe SW, Cepero E and Evan G: Intrinsic
tumour suppression. Nature. 432:307–315. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
148
|
Youle RJ and Strasser A: The BCL-2 protein
family: Opposing activities that mediate cell death. Nat Rev Mol
Cell Biol. 9:47–59. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
149
|
Long J, Menggen Q, Wuren Q, Shi Q and Pi
X: MiR-219-5p inhibits the growth and metastasis of malignant
melanoma by targeting BCL-2. Biomed Res Int. 2017:90325022017.
View Article : Google Scholar : PubMed/NCBI
|
|
150
|
Kang MH and Reynolds CP: Bcl-2 inhibitors:
Targeting mitochondrial apoptotic pathways in cancer therapy. Clin
Cancer Res. 15:1126–1132. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
151
|
Compare D, Rocco A, Liguori E, D'Armiento
FP, Persico G, Masone S, Coppola-Bottazzi E, Suriani R, Romano M
and Nardone G: Global DNA hypomethylation is an early event in
Helicobacter pylori-related gastric carcinogenesis. J Clin
Pathol. 64:677–682. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
152
|
Kim MA, Lee HE, Lee HS, Yang HK and Kim
WH: Expression of apoptosis-related proteins and its clinical
implication in surgically resected gastric carcinoma. Virchows
Arch. 459:503–510. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
153
|
Komatsu S, Ichikawa D, Tsujiura M, Konishi
H, Takeshita H, Nagata H, Kawaguchi T, Hirajima S, Arita T,
Shiozaki A, et al: Prognostic impact of circulating miR-21 in the
plasma of patients with gastric carcinoma. Anticancer Res.
33:271–276. 2013.PubMed/NCBI
|
|
154
|
Okada E, Murai Y, Matsui K, Isizawa S,
Cheng C, Masuda M and Takano Y: Survivin expression in tumor cell
nuclei is predictive of a favorable prognosis in gastric cancer
patients. Cancer Lett. 163:109–116. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
155
|
Ishigami S, Ueno S, Arigami T, Uchikado Y,
Setoyama T, Arima H, Kita Y, Kurahara H, Okumura H, Matsumoto M, et
al: Prognostic impact of CD133 expression in gastric carcinoma.
Anticancer Res. 30:2453–2457. 2010.PubMed/NCBI
|
|
156
|
Hashimoto K, Aoyagi K, Isobe T, Kouhuji K
and Shirouzu K: Expression of CD133 in the cytoplasm is associated
with cancer progression and poor prognosis in gastric cancer.
Gastric Cancer. 17:97–106. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
157
|
Uemura T: The cadherin superfamily at the
synapse: More members, more missions. Cell. 93:1095–1098. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
158
|
Vleminckx K, Vakaet LJ, Mareel M, Fiers W
and van Roy F: Genetic manipulation of E-cadherin expression by
epithelial tumor cells reveals an invasion suppressor role. Cell.
66:107–119. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
159
|
Zhou YN, Xu CP, Han B, Li M, Qiao L, Fang
DC and Yang JM: Expression of E-cadherin and beta-catenin in
gastric carcinoma and its correlation with the clinicopathological
features and patient survival. World J Gastroenterol. 8:987–993.
2002. View Article : Google Scholar : PubMed/NCBI
|
